Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial-Reference-Cited by-同舟云学术

Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial

Published:2019-08 Issue:8 Volume:6 Page:e409-e418
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Sandmaier Brenda M,Kornblit Brian,Storer Barry E,Olesen Gitte,Maris Michael B,Langston Amelia A,Gutman Jonathan A,Petersen Soeren L,Chauncey Thomas R,Bethge Wolfgang A,Pulsipher Michael A,Woolfrey Ann E,Mielcarek Marco,Martin Paul J,Appelbaum Fred R,Flowers Mary E D,Maloney David G,Storb Rainer

Publisher

Elsevier BV

Subject

Hematology

Reference30 articles.

1. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects;McSweeney;Blood,2001

2. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases

3. Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation;Storb;J Clin Oncol,2013

4. A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation;Kornblit;Haematologica,2014

5. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials;Schulz;BMJ,2010

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of interleukin-2 in graft-versus-host disease pathogenesis, prevention and therapy;Cytokine;2024-11

2. Current Approaches for the Prevention and Treatment of Acute and Chronic GVHD;Cells;2024-09-11

3. CMV reactivation during pretransplantation evaluation: a novel risk factor for posttransplantation CMV reactivation;Blood Advances;2024-08-29

4. Post-Transplant-Cyclophosphamide and short-term Everolimus as Graft-versus-Host-Prophylaxis in a real –world cohort of patients with refractory T- and B-cell Lymphoma;2024-08-17

5. Post‐transplant‐cyclophosphamide and short‐term Everolimus as graft‐versus‐host‐prophylaxis in patients with relapsed/refractory lymphoma and myeloma—Final results of the phase II OCTET‐EVER trial;European Journal of Haematology;2024-04-14